Marcus Vetter

Institution: Medical Oncology

Address:

Medical Oncology Petersgraben 4 CH-4031 Basel

Email: marcus.vetter@usb.ch

Group website: www.unispital-basel.ch/das-universitaetsspital/behandlungszentren/tumorzentrum/organtumorzentren/gynaekologisches-tumorzentrum/

Phone: 0041-61-265 2525

Research interests:

Clinical and translational research in the field of breast cancer and gynecologic cancer

Selected publications:

Güth U, Magaton I, Huang DJ, Fisher R, Schötzau A, Vetter M. Primary and secondary distant metastatic breast cancer: Two sides of the same coin. Breast. 2014 Feb;23(1):26-3

Schwab FD, Bürki N, Huang DJ, Heinzelmann-Schwarz V, Schmid SM, Vetter M, Schötzau A, Güth U. Impact of breast cancer family history on tumor detection and tumor size in women newly-diagnosed with invasive breast cancer. Fam Cancer. 2013 Sep 4

Güth U, Myrick ME, Kandler C, Vetter M, The use of adjuvant endocrine breast cancer therapy in the oldest old. Breast. 2013 Mar 27

Güth U, Vetter M, Huang DJ, Heinzelmann-Schwarz V. Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease. Ann Oncol. 2013 Feb;24(2):555-7.

Vetter M, Rochlitz C, Breast cancer - Treatment guidelines and new treatment options in 2012, a medical oncology prospective. Ther Umsch. 2012 Oct;69(10):577-84.

Vetter M, Huang DJ, Bosshard G, Güth U. Breast cancer in women 80 years of age and older: A comprehensive analysis of an underreported entity. Acta Oncol. 2013 Jan;52(1):57-65. doi: 10.3109/0284186X.2012.731523. Epub 2012 Oct 22.

Larkin J, Goh XY, Vetter M, Pickering L, Swanton C, Epigenetic regulation in RCC: opportunities for therapeutic intervention? Nat Rev Urol. 2012 Jan 17.

Gerlinger M, Santos CR, Spencer-Dene B, Martinez P, Endesfelder D, Burrell RA, Vetter M, Jiang M, Saunders RE, Kelly G, Dykema K, Rioux-Leclercq N, Stamp G, Patard JJ, Larkin J, Howell M, Swanton C. Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J Pathol. 2012 Jun;227(2):146-56

Members List